《Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX》.pdfVIP

Online Submissions: /1007-9327office World J Gastroenterol 2010 May 7; 16(17): 2163-2169 wjg@ ISSN 1007-9327 (print) doi:10.3748/wjg.v16.i17.2163 © 2010 Baishideng. All rights reserved. BRIEF ARTICLE Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX Xue-Feng Ni, Chang-Ping Wu, Jing-Ting Jiang Xue-Feng Ni, Chang-Ping Wu, Jing-Ting Jiang, Department © 2010 Baishideng. All rights reserved. of Oncology, The Third Affiliated Hospital, Soochow University, Changzhou 213003, Jiangsu Province, China Key words: Stomach neoplasms; Vascular endothelial Author contributions: Ni XF performed the experiments and growth factor receptor-3; Carcinoembryonic antigen; wrote the paper; Wu CP and Jiang JT supervised the research. Oxaliplatin plus 5-fluorouracil and folinic acid protocol; Correspondence to: Dr. Xue-Feng Ni, Department of Oncol- Survival ogy, The Third Affiliated Hospital, Soochow University, Juqian Road 185, Changzhou 213003, Jiangsu Province, Peer reviewer: Masahiro Iizuka, MD, PhD, Director, Akita China. nxf2010@ Health Care Center, Akita Red Cross Hospital, 3-4-23, Nakadori, Telephone: +86-519 Fax: +86-519 Akita, 010-0001, Japan Received: December 31, 2009 Revised: February 26, 2010 Accepted: March 5, 2010 Ni XF, Wu CP, Jiang JT. Serum V